DIscover CARISEL
A European, open-label, phase III, implementation effectiveness study evaluating every-2-month VOCABRIA + REKAMBYS in real-world settings.[1]
- ViiV Healthcare. Press release: ViiV Healthcare announces start of implementation science study to identify and evaluate approaches to integrating its investigational, every-two-month, injectable HIV treatment in European healthcare practices. Available at: https://viivhealthcare.com/en-us/media-center/news/press-releases/2020/september/viiv-healthcare-announces-start-of-implementation-science-study-/. Accessed February 2024.
REKAMBYS (rilpivirine long-acting injection), including the trademark, is owned by the Janssen Pharmaceutical Companies and used under license by the ViiV Healthcare group of companies. All other trademarks are owned by the ViiV Healthcare group.
PM-GB-CBR-WCNT-240003 | February 2024
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GSK via the GSK Reporting Tool or on 0800 221441.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.
